Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai.
HCC pathogenesis in NASH and impact of Fibrosis
Systemic effects of obesity on cancer development are especially relevant to the liver and involve inflammation, genetics, growth factors, adipokines and microbiomes among others. NASH's immune milieu is distinct and diminishes responses to checkpoint inhibitors. Mechanisms linking fibrosis to hepatocellular carcinoma in NASH include actions of hepatic stellate cells as well as the extracellular matrix; stiffness, for example. As effective NASH therapies and antifibrotic treatments emerge, we should explore their impact on hepatocellular carcinoma mechanisms.Read More
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This video is adapted from a lecture Dr. Scott Friedman gave at the Paris NASH meeting and illustrates the highlights of that topic in this video.Read More
Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials.